<DOC>
	<DOCNO>NCT01442168</DOCNO>
	<brief_summary>The purpose study determine tolerability pharmacokinetics Sevuparin/DF02 administer i.v . infusion combination Malanil® ( atovaquone/proguanil ) anti-malarial treatment subject affect uncomplicated malaria . The study also assess potential Sevupatin/DF02 reduce infect erythrocyte sequestration rosette formation . The study consist dose escalation part ( part 1 ) follow open label , randomized comparison treatment Sevuparin/DF02 Malanil® versus Malanil® alone ( part 2 ) .</brief_summary>
	<brief_title>Sevuparin/DF02 Adjunctive Therapy Subjects Affected With Uncomplicated Falciparum Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Presence acute uncomplicated P. falciparum malaria , confirm positive blood smear asexual form single specie ( P. falciparum ) Counts asexual form P. falciparum : 10 000 100 000/ul without gametocytaemia Presence fever define &gt; 38°C tympanic temperature history fever within last 24 hour Mixed infection Plasmodium species Any criterion severe complicate malaria define WHO , 2010 Use high dos aspirin ( 100 mg/day ) dual antiplatelet therapy use heparin , Low Molecular Weight Heparin ( LMWH ) warfarin Presence significant anemia define Hb &lt; 8 g/dL Hct &lt; 25 % A platelet count &lt; 50,000/μL Presence febrile condition cause disease malaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uncomplicated Falciparum Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Antimalarial treatment</keyword>
	<keyword>Sevuparin/DF02</keyword>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Malanil</keyword>
	<keyword>Peripheral blood parasitemia</keyword>
	<keyword>Rosette formation</keyword>
	<keyword>Maximum tolerate dose</keyword>
</DOC>